Beam Therapeutics 

Yahoo Finance • 7 days ago

Genomics Stocks That Deserve a Place in Your Portfolio in 2026

An updated edition of the Jan. 6, 2026, article. Genomics is the comprehensive study of genomes—the complete set of deoxyribonucleic acid (DNA) within an organism. Rapid scientific progress in this field has intensified interest among pha... Full story

Yahoo Finance • 7 days ago

Walmart downgraded, Etsy upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Barclays upgraded Etsy (ETSY) to Overw... Full story

Yahoo Finance • 11 days ago

Here is Why Beam Therapeutics (BEAM) Appears so Attractive

Beam Therapeutics (NASDAQ:BEAM) is one of the 17 biotechnology stocks with more than 50% upside. On January 22, Patrick Trucchio from H.C. Wainwright maintained a Buy rating on Beam Therapeutics (NASDAQ:BEAM), with a price target of $80.... Full story

Yahoo Finance • 12 days ago

H.C. Wainwright Reiterated Buy on Beam Therapeutics (BEAM) After BEAM-302 FDA Expedited Approval

Beam Therapeutics Inc. (NASDAQ:BEAM) ranks among the best innovative stocks to buy according to Wall Street analysts. H.C. Wainwright reiterated a Buy rating and $80 price target for Beam Therapeutics Inc. (NASDAQ:BEAM) on January 15, citi... Full story

Yahoo Finance • 19 days ago

Cathie Wood buys $43 million of megacap tech stock

It’s been a rocky start to the year for Cathie Wood, the head of Ark Investment Management. As of Feb. 6, Wood’s flagship Ark Innovation ETF (ARKK) was down 9.58% year to date, while the S&P 500 gained 1.27%, as pressure mounted on growth... Full story

Yahoo Finance • 2 months ago

Beam Therapeutics Inc. (BEAM) Reports Updated Data From BEACON Phase 1/2 trial Of Ristoglogene

Beam Therapeutics Inc. (NASDAQ:BEAM) is among the 12 Best Genomics Stocks to Invest In.Is Beam Therapeutics Inc. (BEAM) the Best Gene-Editing Stock to Buy? TheFly reported on December 2, 2025, that Beam Therapeutics Inc. (NASDAQ:BEAM) has... Full story

Yahoo Finance • 2 months ago

Do You Think Beam Therapeutics (BEAM) is an Undervalued Stock?

Contrarius Investment Management, an investment management company, released its third-quarter investor letter for the “Contrarius Global Equity Fund”. A copy of the letter can be downloaded here. The fund’s investor class returned 30.9% i... Full story

Yahoo Finance • 2 months ago

TSLA: Cathie Wood Dumps $30 Million Worth Tesla Stock

This article first appeared on GuruFocus. Cathie Wood's Ark Invest increased stakes in gene-editing and autonomous mobility companies while trimming holdings in Tesla (NASDAQ:TSLA) and Rocket Lab (NASDAQ:RKLB). Selling activity focused o... Full story

Yahoo Finance • 2 months ago

Cathie Wood invests heavily in gene-editing companies, offloads $30 million worth Tesla stock

[Bitcoin 2022 Conference Draws Cryptocurrency Industry Professionals And Investors To Miami] Marco Bello Cathie Wood’s Ark Invest increased exposure to gene-editing names and autonomous mobility companies while further cutting holdings in... Full story

Yahoo Finance • 2 months ago

BEACON Trial Data Makes Beam Therapeutics (BEAM) an Attractive Buy

Beam Therapeutics (NASDAQ:BEAM) is one of the most promising mid-cap healthcare stocks under $50. On December 9, H.C. Wainwright analyst Patrick Trucchio reaffirmed his bullish stance on Beam Therapeutics (NASDAQ:BEAM). He rated the stock... Full story

Yahoo Finance • 2 months ago

Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of B... Full story

Yahoo Finance • 3 months ago

Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting

Updated Data from 31 Adult and Adolescent SCD Patients Treated with risto-cel (Formerly BEAM-101) Show Mean Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to <40%, and Resolution of Anemia Durable for up to 20 Months P... Full story

Yahoo Finance • 3 months ago

Wednesday Sector Leaders: Biotechnology, Trucking Stocks

In trading on Wednesday, biotechnology shares were relative leaders, up on the day by about 4.3%. Leading the group were shares of Capricor Therapeutics, up about 352.3% and shares of Beam Therapeutics up about 11.9% on the day. Also sho... Full story

Yahoo Finance • 3 months ago

Cathie Wood's Ark Invest weekly recap: bets on AI-driven biotech, buys dip in CRCL, sells IRDM, PINS

[Bitcoin 2022 Conference Draws Cryptocurrency Industry Professionals And Investors To Miami] Marco Bello Cathie Wood’s ARK Invest reported a mixed week of aggressive buying in AI, biotech, and digital-asset infrastructure names, while con... Full story

Yahoo Finance • 4 months ago

Cathie Wood Dumps $2.4 Million Worth Of Tesla Shares, Doubles Down On These AI Stocks

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. On Monday, Cathie Wood-led Ark Invest executed significant trades involving Tesla Inc. (NASDAQ:TSLA), Pony AI Inc. (NASDAQ:PONY), Taiwan... Full story

Yahoo Finance • 4 months ago

Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference

CAMBRIDGE, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in a firesid... Full story

Yahoo Finance • 4 months ago

Clear Street Raises PT on Beam Therapeutics (BEAM) to $37 Following Q3 Results

With significant upside potential and hedge fund interest, Beam Therapeutics Inc. (NASDAQ:BEAM) secured a spot on our list of the 15 stocks set to explode in 2026.Clear Street Raises PT on Beam Therapeutics (BEAM) to $37 Following Q3 Resul... Full story

Yahoo Finance • 4 months ago

Cathie Wood's Ark Invest weekly moves: Adds to ACHR and CRSP, trims positions in ROKU and SOFI

[Wooden Blocks with ETF Letters Surrounded by Coins and Financial Icons Representing Investment Growth and Financial Strategies in a Modern Finance Context] Suphachai Panyacharoen Cathie Wood’s ARK Invest reshuffled its portfolio this wee... Full story

Yahoo Finance • 5 months ago

Peek Under The Hood: VB Has 14% Upside

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • 5 months ago

Interesting BEAM Put And Call Options For January 2028

Investors in Beam Therapeutics Inc (Symbol: BEAM) saw new options begin trading today, for the January 2028 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 858... Full story